Introduction
============

Active surveillance (AS) for prostate cancer (PCa) has been historically underutilized but has grown in popularity recently among patients and treating physicians as a way to manage the disease without the morbidity of definitive treatment ([@r1]). The approach is supported by studies demonstrating that AS is a durable option with good long term cancer control in properly selected patient ([@r2]-[@r4]). Recently published updates from large Swedish, US, and Canadian cohorts demonstrate adherence to AS in 60% and 64% of men at 5 years ([@r2],[@r5]) and 55% of men at 15 years ([@r3]), respectively. Studies have also shown remarkably high PCa-specific survival rates for men on AS, ranging from 94.3% in the University of Toronto cohort ([@r3]) to 99.9% in the Johns Hopkins Hospital cohort ([@r4]) at 15 years.

Despite good outcomes with AS, contemporary management with AS is limited by lack of standardized surveillance protocols and poorly defined criteria for proceeding to intervention. The necessity for repeated prostate biopsy among men on AS further exposes them to the morbidity associated with transrectal prostate biopsy, including acute urinary retention, urinary tract infection, bacteremia, and sepsis. A recent study in men on AS found that their odds of infection increased 1.3 times for every prior biopsy ([@r6]), which is especially concerning given the rising rates of multi-drug resistant bacteria and economic burden of hospitalization from severe infections after transrectal biopsy ([@r7]).

Successful management with AS also requires proper candidate selection. A large barrier to successful enrollment and acceptance of AS among patients and their treating physicians is the concern of missing clinically significant cancer and thus losing the opportunity for curative treatment. Traditional enrollment for AS is based upon transrectal ultrasound (TRUS)-guided systematic prostate biopsy (SB), which only samples a small proportion of the gland and is prone to sampling error ([@r8]). This leads to an underestimation of the aggressiveness and extent of disease, with around a third to almost half of men found to have Gleason score (GS) upgrade on radical prostatectomy ([@r9],[@r10]). The poor accuracy of SB in characterizing disease aggressiveness has resulted in the use of repetitive biopsy in men with low risk disease wishing to pursue or remain on AS. In recent years, magnetic resonance imaging (MRI) of the prostate has shown high performance in localizing significant tumors in the prostate ([@r11],[@r12]). MRI assists identification of tumors in areas not well sampled by SB, such as the anterior and apical aspects of the prostate ([@r13]).

Multiple studies have demonstrated improved detection of high-grade cancers using MRI/US fusion-targeted prostate biopsy compared with standard systematic biopsy alone ([@r14]-[@r16]). Given published upgrade rates among contemporary AS cohorts ranging from 24--36% ([@r2],[@r4],[@r17]), MRI-targeted biopsy, in conjunction with SB, may allow for earlier identification of men who are poor surveillance candidates to undergo definitive treatment, sparing them the morbidity of multiple rounds of intervening prostate biopsies prior to treatment. Monitoring of all remaining men without clinically significant disease on AS may also be more cost-effective and yield better quality-adjusted life years compared to current management with TRUS-guided biopsy and serial PSA alone, as suggested by an recent Australian modeling study ([@r18]). In this article, we review the contemporary experience with prostate MRI and MRI-targeted prostate biopsy in the management of men considering AS or in an AS protocol and discuss the potential role for targeted prostate biopsy to improve current AS paradigms in candidate selection and monitoring on AS.

Candidate selection for AS
==========================

The initial challenge for selecting candidates for AS is identifying the population of men with low risk PCa that is unlikely to affective their longevity, can be safely observed, and who are interested in deferring treatment. However, while variation in the definition of low risk or clinically insignificant disease among multiple centers has led to studies with differing AS enrollment criteria, many recent studies have used the following criteria: GS ≤3+3, PSA ≤10 ng/mL, stage ≤ T2 and either ≤2 positive cores or ≤50% per core ([@r1],[@r4],[@r6],[@r13],[@r19]). Multiple PCa risk calculators including D'Amico, Epstein and Cancer of the Prostate Risk assessment (CAPRA) incorporate these clinical-pathologic criteria to help assess eligibility for AS ([@r20]). Men who do not fulfill these criteria are deemed to have clinically significant disease and would be inappropriate for AS. In addition, given the inherent sampling error and high rate of underestimation of the aggressiveness and extent of disease with SB ([@r8]-[@r10]), men enrolling in current AS protocols typically undergo repeat prostate biopsy within one year after initial diagnosis.

Multiple studies have examined the use of MRI of the prostate prior to repeat biopsy in men considering AS. When compared to prostatectomy specimens as the reference standard, Turkbey *et al.* demonstrated that MRI is just as sensitive as D'Amico, Epstein, and CAPRA for determining PCa risk and may even provide additional advantages in selecting men for AS ([@r21]). The presence of visible lesions on MRI can be a negative prognostic factor for low risk disease. In a retrospective analysis of men with PCa diagnosed with SB who met the Prostate Cancer Research International: Active Surveillance (PRIAS) criteria, men with visible lesions on pre-operative MRI prior to radical prostatectomy were more likely to have their cancer status upgraded (50% *vs.* 14%) and be diagnosed with unfavorable disease (52% *vs.* 14%) compared with men with no visible cancer on imaging ([@r22]). In a prospective study of patients on AS, Henderson *et al.* found that the apparent diffusion coefficient (ADC) obtained from the pre-enrollment MRI was a significant predictor of time to adverse histology on biopsy or time to radical treatment. Men with baseline ADC values below the median (972 mm^2^/s in the study) progressed on average seven years earlier than men with ADC values above the median ([@r23]). MRI may also better identify other exclusions for AS compared to SB such as extra-prostatic extension, seminal vesicle involvement, or lymphadenopathy ([@r21],[@r24],[@r25]). While the overall cohort was small, Margel *et al.* reported in a prospective study of 60 men that 32% were reclassified following MRI and repeat conventional biopsy. Of these men, only 8.6% with a normal MRI were reclassified, compared to 77% of men with a \>1 cm lesion on MRI ([@r26]). Studies have also demonstrate good specificity of MRI for evaluation of extra-prostatic extension, supporting the exclusion of men from AS based on the presence of EPE on MRI ([@r27],[@r28]).

The association between level of suspicion on pre-biopsy MRI and likelihood of detection of significant PCa has been demonstrated in multiple studies ([@r15],[@r29],[@r30]). In addition, studies have indicated that a normal MRI has a high negative predictive valve for clinically significant PCa on biopsy ([@r16],[@r31]-[@r33]). Likewise, studies have demonstrated the association between MRI suspicion scores and the rate of upgrade on repeat biopsy in men considering AS ([@r34]-[@r36]). Vargas *et al.* reported on 388 consecutive men with clinically low risk PCa on initial biopsy who underwent pre-biopsy MRI prior to risk stratification biopsy and found that 20% men were upgraded on repeat biopsy ([@r36]). In that study, up to 52% of men had MRI lesions; an MRI suspicion score of 2 or less (based on a 5 point Likert scale) demonstrated high negative predictive value of 0.96--1.0 for upgrading on confirmatory biopsy. In contrast, a suspicion score of 5 had a sensitivity of 0.87--0.98 for upgrade on confirmatory biopsy ([@r36]).

Targeted prostate biopsy has the potential to improve risk assessment through improved sampling of suspicious lesions on MRI in men considering AS. One method of targeted biopsy utilizes in-bore MRI guided biopsy which allows for real-time feedback of needle placement and fewer sampled cores, but does not routinely sample the remaining gland ([@r37]). Using in bore magnetic resonance-guided biopsy (MRGB) of the prostate in 54 consecutive patients with low-risk PCa undergoing inclusion biopsy for AS, Somford *et al.* detected PCa in 55% on repeat biopsy with GS upgrade in 11% of these men. MRI lesions leading to GS upgrade had significantly lower mean ADC compared to those where only low-grade PCa was detected ([@r38]). In total, 45% of men had negative targeted biopsies despite prior histologic diagnosis of PCa on SB, while repeat SB was not performed. In contrast to the low rates of GS upgrade in the Somford study, Felker *et al.* detected PCa in 69% of the 80 men in their AS sub-cohort, with 49% GS upgrade from prior SB ([@r39]). Detection of clinically significant disease increased with higher PI-RADS categories, from only 10% in PI-RADS 3 to 84% in PI-RADS 5 lesions ([@r39]).

MRI-US fusion targeted biopsy (MRF-TB) entails targeting of MRI lesions using a variety of commercial platforms that perform co-registration of the US image and MRI during prostate biopsy ([@r37]). These systems facilitate obtaining targeted samples from MRI visible lesions as well as readily sample the remaining prostate through traditional 12 core systematic biopsies. Prior studies in large cohorts of patients have demonstrated increased detection of high-grade cancers and decreased detection of low-grade cancers with MRF-TB compared to SB, although many of these studies grouped men with mixed biopsy indications (no prior biopsy, prior negative biopsy and prior cancer on SB) for analysis ([@r14]-[@r16],[@r40],[@r41]). Some studies have focused exclusively on men under consideration for AS. In a cohort of 281 men eligible for AS based on prior SB, Ouzzane *et al.* found lesions in 58% of men on MRI, with fusion targeted biopsy reclassifying 10% of men as ineligible for AS based on GS upgrade or large tumor volume ([@r34]). Of these reclassifications, 75% were in men with MRI suspicion score 4 or 5 and 54% were in the anterior prostate. [*Figure 1*](#f1){ref-type="fig"} demonstrates an example of anterior disease missed on SB that was detected with MRI and targeted biopsy from our cohort. Stamatakis *et al.* found that combined systematic and targeted biopsy lead to reclassification in 29% of their cohort of men eligible for AS, of which 60% of reclassifications were due to GS upgrade and the remaining due to increases in percent core length or number of positive cores ([@r42]). Hu *et al.* found similar reclassification rates of 36% on confirmatory systematic and targeted biopsy in 113 men enrolling in AS, with 63% of men reclassified due to GS upgrade to GS 7 or greater and 37% due to higher volume of GS 6 disease ([@r35]). Men with MRI scores of 4 or 5 were reclassified three times as often as men with scores of 2 or 3 ([@r35]), again demonstrating the consistent association between high MRI suspicion scores and detection of significant PCa. While systematic and targeted biopsy results were concordant in 50% of cases, systematic biopsy did detect significant cancer in 11% of men in who targeted biopsy did not find cancer ([@r35]).

![Value of MRI for candidate selection for active surveillance. In this example, a 60-year-old male with rising PSA from 8.4 to 9.9 ng/mL over a 2-year period with two prior transrectal-guided biopsy demonstrating Gleason 3+3 in 1/12 cores each time in the left lateral apex. The patient was interested in pursuing active surveillance and underwent MRI for risk stratification. (A) Axial T2-weighted image shows anterior mid gland to apex lesion involving both the peripheral and transition zones, with extension of tumor beyond the prostate anteriorly; (B) post-contrast image shows focal early enhancement with edges matching lesion on other sequences; (C,D) lesion demonstrates markedly decreased apparent diffusion coefficient value (C) and marked increased signal on ultra high b-value image (D). Lesion measures 26 mm × 13 mm. Lesion was categorized as PI-RADS 5 (clinically significant cancer highly likely). MRI-US fusion-guided targeted biopsy demonstrated Gleason 4+5 and 5+4 cancer in 4/4 cores. Patient subsequently underwent robotic radical prostatectomy demonstrating T3aN0, Gleason 5+4 prostate cancer with positive surgical margins at the bladder neck and underwent adjuvant radiation for his high risk pathology with appropriate PSA nadir following radiation. MRI, magnetic resonance imaging.](tau-06-03-444-f1){#f1}

In contrast to repeat prostate biopsy in men with prior negative SB where only targeted biopsy may be considered given the low detection rate of significant cancer from concordant systematic biopsy ([@r43],[@r44]), targeted biopsy alone in men under consideration for AS appears to miss significant cancer. The difference in reclassification rates between the Ouzzane study and the latter two studies is likely in part related to whether reclassification is determined by targeted biopsy alone versus combined systematic and targeted biopsy. While targeted biopsy clearly identifies significant cancer that is missed by concurrent systematic biopsy in men under consideration for AS, there is persistent concern regarding the occasional missed significant cancer on TB alone ([@r45]). Thus, performing concurrent systematic and targeted biopsy has been advised for optimal risk stratification in this population ([@r46],[@r47]).

Disease progression on AS
=========================

AS allows for monitoring of favorable cancers to delay or avoid treatment unless necessary to avoid overtreatment of insignificant cancers. With this approach, accurate assessment of burden of disease is essential to prevent patients from missing their window for treatment with curative intent upon detection of higher risk or clinically significant disease. While there is no consensus for disease progression, triggers such as PSA kinetics, upgrading in GS score with pattern 4 or 5, and increased volume of disease are generally used as criteria ([@r48]). In this role, MRI functions as an adjunct to the clinical exam, serum PSA, and serial prostate biopsies that form the traditional basis for monitoring, as well as to some of the newer urinary markers, genomic tests, and other PSA-based measurements ([@r48]) ([*Figure 2*](#f2){ref-type="fig"}). In large prospective AS cohorts such as the Sunnybrook cohort, MRI has been employed as an adjunctive test in patients with adverse PSA kinetics ([@r3]). In a prospective study utilizing a subset of the Sunnybrook cohort, 72 men with a median time of 38 months on AS were referred for biopsy due to rising PSA and underwent pre-biopsy MRI followed by targeted and systematic 12-core biopsy demonstrating a reclassification rate of 43% for clinically significant cancer ([@r49]). Of these reclassifications, 26% were due to upgrade to GS 7 while 17 were was due to GS 6 with \>50% involvement in any core. Overall, targeted biopsy detected more cancers alone than systematic biopsy, and in the cases where two biopsy methods had concordant results, targeted biopsy had significantly higher maximum cancer-core lengths compared to systematic ([@r49]). As was the case with confirmatory biopsies, for men on AS, the MRI score correlated with cancer detection rates, with PPV of 49% for GS 7 cancer and 78% for GS 6 with any core with \>50% involvement for men with MRI score ≥4 and a NPV of 97% for GS ≥7 cancer with a MRI score ≤3 ([@r49]).

![Detection of disease progression on active surveillance with MRI. In this example, a 65-year-old male with PSA of 3.56 ng/mL and known Gleason 3+3 prostate cancer in 2/12 cores with increasing lesion size on follow up prostate MRI. (A-C) Baseline MRI demonstrating left posteromedial base peripheral zone lesion on axial T2-weighted image (A), early post-contrast image (B) and apparent diffusion coefficient map (C) measuring 3 mm × 5 mm in size; (D-F) follow-up MRI obtained 1 year later demonstrates increase in size of lesion to 8 mm × 8 mm in size, as demonstrated on axial T2-weighted image (D), early post-contrast image (E) and apparent diffusion coefficient map (F). Lesion was categorized as PI-RADS 4 (clinically significant cancer likely). MRI-US fusion-guided targeted biopsy demonstrated Gleason 3+4 and 4+3 cancer in 3/4 cores with Gleason 3+3 and 3+4 in 2/12 cores on systematic biopsy. Patient subsequently underwent robotic radical prostatectomy demonstrating T2cN0, Gleason 3+4 prostate cancer with negative surgical margins. MRI, magnetic resonance imaging.](tau-06-03-444-f2){#f2}

Other recent studies have examined the reclassification rates of men undergoing MRI and targeted prostate biopsy as part of the routine monitoring process while enrolled in AS protocols. Of the 130/253 men in the Ouzzane cohort who elected for AS after confirmatory targeted biopsy, repeat biopsy and MRI at 1 year follow-up led to reclassification in 29% ([@r34]). However, given the low reclassification rate of only 10% on initial targeted biopsy in this cohort ([@r34]), it is likely that a subset of these upgrades on repeat biopsy may be attributed to targeting error on initial biopsy rather than progression of disease. Ma *et al.* recently reported on a AS cohort of 103 men with a median follow-up of 5 years and 3 prior biopsies who underwent combined SB and TB after MRI demonstrating 24% upgrade to GS ≥7. Of note, SB detected a significantly larger proportion of GS ≥7 compared to TB (20% *vs.* 7%), with addition of TB to SB only leading to detection of additional 4% of GS ≥7 cancer ([@r50]). SB also detected 56% cancer overall and 10% GS ≥7 cancer in the 127 on AS with PI-RADS 1 or 2 lesions who only underwent SB ([@r50]). Frye *et al.* also recently published a study examining the rates of progression of disease for 166 men on AS who were followed by targeted prostate biopsies using a fusion platform and observed progression in 30% of men over a mean follow-up of 25.5 months. In contrast to the Ma study, of the 49 men who progressed on repeat biopsy, TB identified significantly more men who progressed compared to SB (45% versus 31%), with progression detected in 25% by both biopsy techniques ([@r51]).

While AS was only offered to men with small volume GS 6 PCa in the original Epstein criteria, various programs have expanded the criteria to include men with more extensive GS 3+3 lesions or small volume GS 3+4 PCa ([@r48]). Pathologic upgrading has been observed more often in men with GS 3+4 and intermediate risk PCa compared to men with low risk lesions in prior cohorts utilizing conventional TRUS biopsy for enrollment ([@r48]). However, as MRI and fusion targeted biopsy holds the potential to more accurately exclude men with clinically significant cancer from AS, questions remain regarding progression rates on AS in a cohort selected by fusion targeted biopsy. To help answer this question, Nassiri *et al.* evaluated the upgrade rate in 196 men with GS 6 and 63 men with GS 3+4 PCa who were placed on AS after diagnosis by fusion targeted biopsy. Overall, 13% of men progressed to GS ≥4+3 PCa. However, men with initial GS 3+4 PCa on diagnosis were 2.8 times (25% *vs.* 9%) more likely to progress to GS ≥4+3 PCa at 3 years compared to men with only initial GS 6 PCa ([@r52]). Other independent predictors of upgrade in the study include PSA density (PSAD) ≥0.15 ng/mL/cm^3^ and presence of a MRI score 5 lesion ([@r52]).

Further long term outcome data is necessary to establish the role of monitoring for disease progression using serial MRI examinations instead of biopsy in men on AS. In a pilot study by Morgan *et al.*, ADC values were found to be significantly reduced over serial MRI examinations two years apart in men who progressed to radical treatment based on PSA velocity or adverse features on biopsy compared to men who remained on AS ([@r53]). A 10% reduction in tumor ADC values indicated progression with 93% sensitivity in the study ([@r53]). Conversely, in a cohort of 58 men on AS undergoing MRI both at baseline and prior to repeat biopsy, stable MRI findings had a negative predictive value of 80% for GS upgrade on biopsy ([@r54]). This early data suggests a potential role for non-invasive monitoring of patients with serial MRI at set intervals, with prostate biopsies only performed for changes on MRI. This practice holds the potential to significantly decrease the number of prostate biopsies performed for men on AS. Using a MRI based AS nomogram to determine whether repeat biopsy was indicated, Siddiqui *et al.* reports that around 47--68% of the AS cohort could potentially be spared prostate biopsy based on MRI findings ([@r55]). Further data is also needed regarding rates of upgrade or reclassification for men with stable MRI findings but changes in PSA or clinical exam over time to help inform whether prostate biopsy is necessary in this setting.

Conclusions
===========

Prostate MRI, either alone or in conjunction with MRI-targeted prostate biopsy, has the potential to significantly improve our current AS paradigm, both in early exclusion of men unsuitable for AS and improved monitoring of men on AS. Improved risk stratification using MRI and targeted prostate biopsy would help allay patient and physician concerns over missed occult clinically significant cancer. Improved confidence in the candidate selection process for AS will only increase its utilization moving forward. While recent literature supports the use of MRI and targeted prostate biopsy in men with known PCa, there are important questions remaining to be answered. For example, reclassification rates on repeat biopsy are heterogeneous across studies, and data are conflicting regarding the relative performance of systematic versus targeted biopsy in the AS setting. Further research is warranted to better understand the nature of clinically significant cancers that are missed on MRI, and why certain men have progression of disease that is not visible on prostate MRI. Consensus is also needed over what constitutes progression on MRI, when prostate biopsy can be safely avoided, and how to best utilize this additional information in current AS protocols. Such insights will expand upon recent advancements in the field to further optimize the clinical management of patients on AS.
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